Table 1.
Baseline characteristics of men with prostate cancer by ADT use
| All patients | ADT-free cohort | ADT users | AA | GnRH | P value* | |
| n (%) | 27 580 (100) | 14 502 (52.6) | 13 078 (47.4) | 1014 (7.8) | 12 064 (92.2) | |
| Mean follow-up time, years (SE) | 6.74 (3.64) | 6.54 (3.56) | 6.97 (3.73) | 7.12 (4.34) | 6.95 (3.68) | |
| Age | ||||||
| Mean age at diagnosis, years (SE) |
67.81 (8.61) | 68.71 (10.05) | 66.81 (6.53) | 66.10 (6.50) | 66.87 (6.53) | <0.001 |
| <65 | 9327 (33.9%) | 5120 (35.3%) | 4207 (32.2%) | 374 (36.9%) | 3833 (31.8%) | |
| 65–74 | 12 441 (45.1%) | 4715 (32.5%) | 7726 (59.0%) | 580 (57.2%) | 7146 (59.2%) | |
| >75 | 5812 (21.0%) | 4667 (32.2%) | 1145 (8.8%) | 60 (5.9%) | 1085 (9.0%) | |
| Stage | ||||||
| I | 1913 (6.9%) | 1380 (9.5%) | 533 (4.0%) | 25 (2.5%) | 508 (4.2%) | <0.001 |
| II | 11 986 (43.5%) | 6660 (45.9%) | 5326 (40.8%) | 460 (45.3%) | 4866 (40.4%) | |
| III | 7157 (25.9%) | 2671 (18.4%) | 4486 (34.3%) | 214 (21.1%) | 4272 (35.4%) | |
| IV | 1461 (5.3%) | 663 (4.6%) | 798 (6.1%) | 105 (10.4%) | 693 (5.7%) | |
| Unknown | 5063 (18.4%) | 3128 (21.6%) | 1935 (14.8%) | 210 (20.7%) | 1725 (14.3%) | |
*Shows significance of differences between the ADT-free cohort and ADT users.
AA, antiandrogen; ADT, androgen deprivation therapy; GnRH, gonadotropin-releasing hormone.